Establishment of xenografts and methods to evaluate tumor burden for the three most frequent subclasses of pediatric-type diffuse high grade gliomas.
Por:
Balaguer-Lluna L, Gene-Olaciregui N, Aschero MR, Resa-Parés C, Paco-Mercader S, Cuadrado-Vilanova M, Burgeño-Sandoval V, Baulenas-Farrés M, Monterrubio C, Manzanares-Quintela A, Rodriguez E, Lavarino C, Mora J and Carcaboso AM
Publicada:
1 may 2025
Ahead of Print:
17 feb 2025
Resumen:
PURPOSE: We aimed to expand and refine the experimental models for pediatric-type diffuse high grade gliomas (pHGG) and the methods to follow up disease progression in mouse pHGG xenografts. METHODS: Using whole exome sequencing and immunoassays we characterized pHGG primary cultures and xenografts established at hospital SJD Barcelona. We obtained tumor samples and serial CSF samples from mouse xenografts. To assess tumor progression, we evaluated: (1) mouse weight, (2) human cell counts in brain paraffin sections, and (3) tumor DNA amount, quantified through droplet digital polymerase chain reaction (ddPCR) in paraffin sections and cerebrospinal fluid (CSF). RESULTS: We established 15 experimental models of three pHGG subclasses, four of which engrafted in mice. Xenografts HSJD-DIPG-007 and HSJD-DMG-005 are diffuse midline glioma (DMG) H3 K27-altered, HSJD-GBM-002 is an H3 G34-mutant diffuse hemispheric glioma, and HSJD-GBM-001 is an H3-wildtype and IDH-wildtype pHGG. ddPCR quantification of human H3F3A K27M, H3F3A G34R, and ACVR1 R206H in paraffin samples is linear and sufficiently sensitive. We required a preamplification step to detect H3F3A K27M in CSF. In HSJD-DIPG-007 xenografts, human cell counts correlated with H3F3A amounts in paraffin for the whole engraftment period. Weight loss correlated with human cell counts and H3F3A amounts in paraffin. Serial collection of CSF was feasible, but H3F3A amounts in the CSF correlated only with weight loss. CONCLUSION: The developed methods contribute to the preclinical field of pHGG and introduce for the first time the concept of liquid biopsy in mice, which still needs improvement regarding its use as a preclinical biomarker.
Filiaciones:
Balaguer-Lluna L:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Gene-Olaciregui N:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Aschero MR:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Resa-Parés C:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Paco-Mercader S:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Cuadrado-Vilanova M:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Burgeño-Sandoval V:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Baulenas-Farrés M:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Monterrubio C:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Manzanares-Quintela A:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Rodriguez E:
Pathology, Hospital Sant Joan de Deu, Barcelona, 08950, Spain
Lavarino C:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Mora J:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Carcaboso AM:
Pediatric Cancer Program, Institut de Recerca Sant Joan de Deu (IRSJD), Barcelona, 08950, Spain
SJD Pediatric Cancer Center Barcelona, Hospital Sant Joan de Deu, Santa Rosa 39-57, Esplugues de Llobregat, Barcelona, 08950, Spain
Inst Recerca St Joan Deu IRSJD, Pediat Canc Program, Barcelona 08950,
Spain
Hosp St Joan Deu, SJD Pediat Canc Ctr Barcelona, Santa Rosa 39-57,
Esplugas de Llobregat 08950, Barcelona, Spain
Hosp St Joan Deu, Pathol, Barcelona 08950, Spain
Green Submitted, hybrid
|